Art. 12 Regulation (EU) 2025/117

Consultation of stakeholder organisations during joint scientific consultation

In forcesince 24 Jan 2025
1.

At any time during the joint scientific consultation, the JSC Subgroup, via the HTA secretariat, may seek input on the medical condition, therapeutic area or other areas relevant for the medical device or in vitro diagnostic medical device from patient organisations, healthcare professional organisations or clinical and learned societies via the members of the stakeholder network established pursuant to Article 29 of Regulation (EU) 2021/2282, whilst respecting the confidential nature of the request for joint scientific consultation.

2.

Where the joint scientific consultation on medical devices is carried out in parallel with the expert panel consultation, the HTA secretariat shall share the input referred to in paragraph 1 with the European Medicines Agency at the same time as sharing it with the JSC Subgroup.